Y-Intercept (HK)’s Corbus Pharmaceuticals CRBP Stock Holding History

Y-Intercept (HK)’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$212K	Buy	+22,646	New	+$214K	﹤0.01%	1563
2025 Q3	–	Sell	-20,437	Closed	-$141K	–	1638
2025 Q2	$141K	Buy	+20,437	New	+$148K	﹤0.01%	1505
2024 Q4	–	Sell	-18,372	Closed	-$379K	–	1262
2024 Q3	$379K	Buy	+18,372	New	+$940K	0.02%	915
2021 Q3	–	Sell	-682	Closed	-$37K	–	690
2021 Q2	$37K	Buy	+682	New	+$37.8K	0.01%	568

Other funds holding CRBP

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

SWM

Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

Y-Intercept (HK)'s CRBP Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Corbus Pharmaceuticals (CRBP) in Q2 2026: 22,646 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #1563 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in CRBP as recently as Q2 2025.

Y-Intercept (HK) first reported a position in CRBP in Q2 2021 and has held it in 4 quarters since. The position peaked at $379K in Q3 2024. 6 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

Y-Intercept (HK) held 22,646 shares of Corbus Pharmaceuticals worth $212K as of Q2 2026.
Corbus Pharmaceuticals was a new Y-Intercept (HK) position in Q2 2026.
Corbus Pharmaceuticals made up ﹤0.01% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1563 holding.
Y-Intercept (HK) first reported a position in Corbus Pharmaceuticals in Q2 2021 and has held it in 4 quarters since.
Y-Intercept (HK)'s Corbus Pharmaceuticals position peaked at $379K in Q3 2024.
6 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.